COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND VEMURAFENIB, AND METHODS OF USE

• 收藏
• 分享

专利权人:

Genentech Inc.

发明人:

HOEFLICH, Klaus,MERCHANT, Mark

申请号：

HK14112699.3

公开号：

HK1199244B

申请日:

2014.12.18

申请国别(地区):

HK

年份:

2017

代理人:

摘要：

or a pharmaceutically acceptable salt thereof wherein R1, R2, R5, R10, and A have any of the values defined in the specification and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/